An inverse relationship between ER activity and EGFR and HER2 expression has been reported in clinical breast cancer, with overexpression of these receptor tyrosine kinases being associated with decreased sensitivity to endocrine therapy and a poorer prognosis [53–55]. This evidence concerns the gene ERBB2 and breast carcinoma.